AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1717776 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg)
Number of subjects: 8
Study 1717776 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine (5 mg)
Number of subjects: 8
Study 1717776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of benazepril and cadralazine
Number of subjects: 8
Study 1717776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6355533 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil hydrochloride, 80 mg four times daily
Number of subjects: 12
Study 6355533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 4003239 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 25
Study 4003239 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 25
Study 4003239 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg
Number of subjects: 25
Study 4003239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 4003239 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (all doses combined)
Number of subjects: 25
Study 29134277 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.5/17.5 Fr Miniperc (group A)
Number of subjects: 123
Study 29134277 — intervention group
Group type: COMPARATOR
Intervention: 22/24 Fr standard PCNL (group B)
Number of subjects: 123
Study 26442902 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate dialysate (CiDi)
Number of subjects: 92
Study 26442902 — intervention group
Group type: COMPARATOR
Intervention: Standard dialysate (StDi)
Number of subjects: 92
Study 24569536 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yoghurt
Number of subjects: 156
Study 24569536 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules
Number of subjects: 156
Study 24569536 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 156
Study 24569536 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 156
Study 22424822 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily for 12 weeks)
Number of subjects: 52
Study 22424822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19657590 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg alfacalcidol (D)
Number of subjects: 137
Study 19657590 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg raloxifene (R)
Number of subjects: 137
Study 19657590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 microg alfacalcidol and 60 mg raloxifene (D + R)
Number of subjects: 137
Study 19657590 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 137
Study 19657590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-compliance patients (MPR > 80%) treated with raloxifene alone or with alfacalcidol
Number of subjects: 137
Study 18754270 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin 80 mg + ezetimibe 10 mg
Number of subjects: 720
Study 18754270 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 80 mg + placebo
Number of subjects: 720
Study 16869135 — intervention group
Group type: EXPERIMENTAL
Intervention: Friction braked cycle ergometry with resistive forces reflecting fat-free mass (FFM)
Number of subjects: 11
Study 16869135 — intervention group
Group type: COMPARATOR
Intervention: Friction braked cycle ergometry with resistive forces reflecting total-body mass (TBM)
Number of subjects: 11
Study 11273847 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy+ protein (80 mg aglycone isoflavones, 42 g/d)
Number of subjects: 94
Study 11273847 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy- protein (trace amounts of isoflavones, 42 g/d)
Number of subjects: 94
Study 11273847 — intervention group
Group type: COMPARATOR
Intervention: Milk protein (42 g/d)
Number of subjects: 94
Study 11273847 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 94
Study 9555964 — intervention group
Group type: EXPERIMENTAL
Intervention: BioMedicus centrifugal pump (CP)
Number of subjects: 1000
Study 9555964 — intervention group
Group type: COMPARATOR
Intervention: roller pump
Number of subjects: 1000
Study 8296708 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF (2 micrograms/kg intravenously) plus furosemide (1.3 mg/kg intravenously)
Number of subjects: 14
Study 8296708 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus furosemide (1.3 mg/kg intravenously)
Number of subjects: 14
Study 3190990 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after no premedication
Number of subjects: 7
Study 3190990 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl 1.4 mg kg‐1 by i.m. injection after two oral doses of 400 mg cimetidine
Number of subjects: 7
Study 29211967 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPH EROS (10-20 mg/day)
Number of subjects: 99
Study 29211967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 26969128 — intervention group
Group type: EXPERIMENTAL
Intervention: The Feeling Safe Programme
Number of subjects: 150
Study 26969128 — intervention group
Group type: COMPARATOR
Intervention: Befriending (control)
Number of subjects: 150
Study 24803285 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week structured cognitive training program
Number of subjects: 21
Study 24803285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 22497790 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer dialysis catheters (20-24 cm)
Number of subjects: 100
Study 22497790 — intervention group
Group type: COMPARATOR
Intervention: Shorter dialysis catheters (15-20 cm)
Number of subjects: 100
Study 20233525 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuit (CC)
Number of subjects: 60
Study 20233525 — intervention group
Group type: COMPARATOR
Intervention: Semi-closed circuit (SCC) at 4 l/min
Number of subjects: 60
Study 20233525 — intervention group
Group type: COMPARATOR
Intervention: Semi-closed circuit (SCC) at 2 l/min
Number of subjects: 60
Study 18576922 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute massage
Number of subjects: 14
Study 18576922 — intervention group
Group type: COMPARATOR
Intervention: 20-minute reading period (control)
Number of subjects: 14
Study 15801245 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine-pseudoephedrine, 5/240-mg tablets
Number of subjects: 1121
Study 15801245 — intervention group
Group type: COMPARATOR
Intervention: Desloratadine, 5 mg
Number of subjects: 1121
Study 15801245 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine, 240 mg
Number of subjects: 1121
Study 12428229 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint distraction
Number of subjects: 57
Study 10543296 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 20
Study 10543296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7787145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Group #1, MAP < or = 92 mm Hg
Number of subjects: 0
Study 7787145 — intervention group
Group type: COMPARATOR
Intervention: Moderate Group #2, MAP 100 to 107 mm Hg
Number of subjects: 0
Study 7787145 — intervention group
Group type: COMPARATOR
Intervention: Captopril (previous study)
Number of subjects: 0
Study 2194055 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin (RKM) dry syrup at approximately 30 mg/kg body weight for 5 days
Number of subjects: 0
Study 2194055 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (FOM) dry syrup at 60 mg/kg body weight for 5 days
Number of subjects: 0
Study 2194055 — intervention group
Group type: EXPERIMENTAL
Intervention: Rokitamycin (RKM) dry syrup
Number of subjects: 0
Study 2194055 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin (FOM) dry syrup
Number of subjects: 0
Study 361512 — intervention group
Group type: EXPERIMENTAL
Intervention: Deglycyrrhizinised liquorice
Number of subjects: 96
Study 361512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29501108 — intervention group
Group type: EXPERIMENTAL
Intervention: Active AcceleDent Aura device (OrthoAccel Technologies, Inc.)
Number of subjects: 27
Study 29501108 — intervention group
Group type: COMPARATOR
Intervention: Sham AcceleDent Aura device
Number of subjects: 27
Study 27044326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 25 μg
Number of subjects: 456
Study 27044326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 6.25 μg and VI 12.5 μg
Number of subjects: 456
Study 27044326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 456
Study 27044326 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (VI) 6.25 μg, VI 12.5 μg, VI 25 μg
Number of subjects: 456
Study 27044326 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fluticasone propionate (FP)
Number of subjects: 456
Study 24948656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (400 mg twice daily)
Number of subjects: 207
Study 24948656 — intervention group
Group type: COMPARATOR
Intervention: Imatinib
Number of subjects: 207
Study 22885502 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-root extraction
Number of subjects: 40
Study 22885502 — intervention group
Group type: COMPARATOR
Intervention: Medial resistance removal
Number of subjects: 40
Study 19933173 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lung ventilation (recruitment manoeuvres, tidal volume 6 ml kg(‐1) predicted body weight, and 12 cm H(2)O PEEP)
Number of subjects: 40
Study 19933173 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (no recruitment manoeuvres, tidal volume 10 ml kg(‐1) predicted body weight, and zero end‐expiratory pressure)
Number of subjects: 40
Study 17367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at RAA using up to 10 consecutive 20-Hz trains followed by pacing at CS-Os if RAA pacing failed
Number of subjects: 110
Study 17367351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at CS-Os using the same stimulation protocol followed by HF pacing at RAA
Number of subjects: 110
Study 17367351 — intervention group
Group type: EXPERIMENTAL
Intervention: HF pacing at CS-Os
Number of subjects: 110
Study 17367351 — intervention group
Group type: COMPARATOR
Intervention: Observation up to 6 minutes (no pacing)
Number of subjects: 110
Study 15613434 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E(2))
Number of subjects: 13
Study 15613434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 13
Study 12172049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lincomycin mixed with 0.05% betamethasone valerate and 2% linoleic acid (group C)
Number of subjects: 47
Study 12172049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lincomycin mixed with 0.05% betamethasone valerate (group B)
Number of subjects: 47
Study 12172049 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (group A)
Number of subjects: 47
Study 10608202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (11.4 +/- 0.9 microg x kg(‐1) x min(‐1))
Number of subjects: 36
Study 10608202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (8.1 +/- 0.8 microg x kg(‐1) x min(‐1))
Number of subjects: 36
Study 10608202 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diltiazem (0.25 +/- 0.01 mg x kg(‐1)) and nicardipine (5.9 +/- 0.9 microg x kg(‐1) x min(‐1))
Number of subjects: 36
Study 10608202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 36
Study 10608202 — intervention group
Group type: EXPERIMENTAL
Intervention: Group N (Nicardipine)
Number of subjects: 36
Study 7723960 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 20
Study 7723960 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 20
Study 2040131 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermography
Number of subjects: 24
Study 2040131 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-Doppler flowmetry (LDF)
Number of subjects: 24
Study 2040131 — intervention group
Group type: COMPARATOR
Intervention: Smoking two 1.1 mg nicotine cigarettes
Number of subjects: 24
Study 2040131 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of maximum responses during a 45-min period after smoking
Number of subjects: 24
Study 2040131 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproducibility of responses
Number of subjects: 24
Study 6104615 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg for 3 weeks
Number of subjects: 0
Study 30392112 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care intervention with usual care
Number of subjects: 28
Study 30392112 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 27839965 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel therapy (2mL/cm2 of ulcers), performed weekly for 4 weeks
Number of subjects: 70
Study 27839965 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel therapy
Number of subjects: 70
Study 25641535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin I (cTnI) measured at various time points post-PCI
Number of subjects: 1066
Study 25641535 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnI added to baseline risk model
Number of subjects: 1066
Study 24379229 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAMP nutrition (12% glucose, 3.8 g/kg per day protein/lipid)
Number of subjects: 150
Study 24379229 — intervention group
Group type: COMPARATOR
Intervention: Control PN (10% glucose, 2.8 g/kg per day protein/lipid)
Number of subjects: 150
Study 20861716 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical food (Theramine) alone (n = 43)
Number of subjects: 129
Study 20861716 — intervention group
Group type: COMPARATOR
Intervention: Naproxen alone (250 mg/d, n = 42)
Number of subjects: 129
Study 20861716 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical food (Theramine) with naproxen (n = 44)
Number of subjects: 129
Study 19503811 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (glitazone)
Number of subjects: 61
Study 19503811 — intervention group
Group type: COMPARATOR
Intervention: Comparator drug
Number of subjects: 61
Study 19503811 — intervention group
Group type: COMPARATOR
Intervention: Higher impact factor journals
Number of subjects: 61
Study 17462946 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricuspid annular plane systolic excursion (TAPSE) measurement
Number of subjects: 817
Study 17462946 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of chronic obstructive pulmonary disease (COPD)
Number of subjects: 817
Study 15064872 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-TRODAT-1 (TR)
Number of subjects: 96
Study 15064872 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-FP-beta-CIT (FP)
Number of subjects: 96
Study 11809253 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention (counselling and nicotine replacement therapy, with smoking cessation or at least 50% smoking reduction)
Number of subjects: 120
Study 11809253 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 120
Study 11809253 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 120
Study 9524512 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 degrees fixed angle blade‐plate (group A)
Number of subjects: 233
Study 9524512 — intervention group
Group type: COMPARATOR
Intervention: 135 degrees compression hip screw (group B)
Number of subjects: 233
Study 1439512 — intervention group
Group type: EXPERIMENTAL
Intervention: Takeda Medical (A & D) TM 2420
Number of subjects: 85
Study 1439512 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random-zero sphygmomanometer
Number of subjects: 85
Study 1439512 — intervention group
Group type: EXPERIMENTAL
Intervention: TM 2420
Number of subjects: 85
Study 3739807 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence goal preference
Number of subjects: 46
Study 3739807 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal persuasion indicators
Number of subjects: 46
Study 3739807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence indicators
Number of subjects: 46
Study 3739807 — intervention group
Group type: EXPERIMENTAL
Intervention: SADQ scores and Rand definite alcoholism
Number of subjects: 46
Study 31567304 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Relaxation Exercises (PRE)
Number of subjects: 96
Study 31567304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 30027429 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐chemo
Number of subjects: 123
Study 30027429 — intervention group
Group type: COMPARATOR
Intervention: R‐chemo
Number of subjects: 123
Study 27702715 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC treatment, 65 mg caffeine/cup)
Number of subjects: 42
Study 27702715 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (DC treatment, 99.9% caffeine‐free)
Number of subjects: 42
Study 27702715 — intervention group
Group type: COMPARATOR
Intervention: Boiled water (BW treatment)
Number of subjects: 42
Study 25108590 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induction
Number of subjects: 80
Study 25108590 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral mood induction
Number of subjects: 80
Study 22159820 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 14
Study 22159820 — intervention group
Group type: COMPARATOR
Intervention: No exercise (CON)
Number of subjects: 14
Study 19927038 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise (LI)
Number of subjects: 9
Study 19927038 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HI)
Number of subjects: 9
Study 19927038 — intervention group
Group type: COMPARATOR
Intervention: No exercise (NE)
Number of subjects: 9
Study 17434828 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin treatment (groups A and B)
Number of subjects: 132
Study 17434828 — intervention group
Group type: COMPARATOR
Intervention: Positive control (group C)
Number of subjects: 132
Study 17434828 — intervention group
Group type: COMPARATOR
Intervention: Negative control (group D)
Number of subjects: 132
Study 15860390 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg
Number of subjects: 335
Study 15860390 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin 2 mg
Number of subjects: 335
Study 15860390 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 335
Study 15860390 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS
Number of subjects: 335
Study 15860390 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of doxazosin
Number of subjects: 335
Study 15860390 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin GITS and doxazosin
Number of subjects: 335
Study 15860390 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 335
Study 11973182 — intervention group
Group type: COMPARATOR
Intervention: S(+)‐ketamine 1 mg/kg alone (Group K)
Number of subjects: 53
Study 11973182 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1 mg/kg with clonidine 1 microg/kg (Group C1)
Number of subjects: 53
Study 11973182 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1 mg/kg with clonidine 2 microg/kg (Group C2)
Number of subjects: 53
Study 9474068 — intervention group
Group type: EXPERIMENTAL
Intervention: RCTs (Randomized Controlled Trials)
Number of subjects: 13
Study 9474068 — intervention group
Group type: COMPARATOR
Intervention: Case-Control Studies
Number of subjects: 13
Study 9474068 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted RCT results
Number of subjects: 13
Study 9474068 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy of mammography in women aged 50 years and above
Number of subjects: 13
Study 7674231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CysA) 5 mg/kg daily
Number of subjects: 24
Study 7674231 — intervention group
Group type: COMPARATOR
Intervention: Hydroxychloroquine (OH-Chlor) 6 mg/kg daily
Number of subjects: 24
Study 2248081 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 4 mg/kg
Number of subjects: 10
Study 2248081 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide 6.5 mg/kg
Number of subjects: 10
Study 2248081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7345161 — intervention group
Group type: EXPERIMENTAL
Intervention: PC muscle exercises
Number of subjects: 46
Study 7345161 — intervention group
Group type: COMPARATOR
Intervention: Relaxation exercises
Number of subjects: 46
Study 7345161 — intervention group
Group type: COMPARATOR
Intervention: Attention-control group
Number of subjects: 46
Study 31699734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D intervention enacting recommended care for multimorbidity
Number of subjects: 1546
Study 28837443 — intervention group
Group type: EXPERIMENTAL
Intervention: cathodal transcranial direct current stimulation (c‐tDCS) to unaffected primary motor cortex (PMC) plus conventional occupational therapy (OT)
Number of subjects: 16
Study 28837443 — intervention group
Group type: COMPARATOR
Intervention: sham transcranial direct current stimulation plus conventional occupational therapy (OT)
Number of subjects: 16
Study 25749908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (10 or 20 mg of zinc sulphate for 2-5 month-old or 6-59 month-old children, respectively, during 10 days)
Number of subjects: 87
Study 25749908 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 87
Study 25749908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 23403171 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether/lumefantrine (AL)
Number of subjects: 1682
Study 21159035 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (200 mg intravenously daily on days 1-4)
Number of subjects: 40
Study 21159035 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (200 mg intravenously daily on days 1-4) + recombinant human erythropoietin (10,000E)
Number of subjects: 40
Study 19214375 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day alendronate (Group A)
Number of subjects: 199